Chemotherapy and Immunotherapy Options for Genitourinary Malignancies Webcast (2017)

This course will review the current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, and prostate cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a panel discussion with an interactive component. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects.

Learning Objectives

After attending this course, participants will be able to:

  1. obtain familiarization with standard of care chemotherapy regimens for genitourinary malignancies
  2. obtain familiarization with newer immunotherapy options in the treatment of genitourinary malignancies
  3. enhance the identification and management of toxicities with relation to these agents
  4. identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
06/01/2017
Course expires: 
06/01/2018
Rating: 
0

Faculty Disclosures
Course Director:

  • Costas Lallas, MD: Nothing to disclose

Faculty:

  • Anne Calvaresi, MSN, CRNP: Nothing to disclose
  • Edouard Trabulsi, MD, FACS: Nothing to disclose


Planner Disclosures
Education Council

  • Timothy Charles Brand, M.D.: Nothing to disclose
  • Anthony A. Caldamone MD: Nothing to disclose
  • Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
  • Sam S. Chang, MD: astellas: Consultant or Advisor; NIH: Scientific Study or Trial; GLG: Consultant or Advisor; Janssen: Consultant or Advisor; tolmar: Consultant or Advisor
  • Matthew S. Christman MD: Nothing to disclose
  • Jody Donaldson m (AUA Staff): Nothing to disclose
  • Shelby Englert (AUA Staff): Nothing to disclose
  • Matthew Thomas Gettman, MD: Nothing to disclose
  • Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
  • Howard B. Goldman, MD: allergan: Consultant or Advisor; astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor
  • William C. Huang, MD: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
  • William C. Hulbert Jr. MD: Nothing to disclose
  • Brant Inman, M.D., MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor
  • Mark L. Jordan MD,FACS: Nothing to disclose
  • Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research; Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
  • Martin A. Koyle MD: Nothing to disclose
  • John Stephen Lam MD: Nothing to disclose
  • Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial: Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
  • Nicole Lara Miller ,MD: Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
  • Manoj Monga, MD, FACS: Fortec: Other; endourology society: Leadership Position
  • Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
  • Christopher Porter, MD: Nothing to disclose
  • Gail S. Prins PhD: Nothing to disclose
  • Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; Gaudium: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
  • Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Pacific Edge Biotechnology: Scientific Study or Trial
  • Lee Richstone, MD: Nothing to disclose
  • Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
  • Karl-Dietrich Sievert ,MD, PhD: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
  • Joseph A. Smith Jr.,MD: Nothing to disclose
  • Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
  • Edouard John Trabulsi, MD: Nothing to disclose

Method of Participation
Learners will participate in this online educational activity by taking an online pre- and post-test and viewing the online video. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 2 hours
 
Release Date: June, 2017
Expiration Date: June, 2018
 
Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation
The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
 
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy 
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Acknowledgements
The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:
 
AbbVie
Astellas
Bayer HealthCare Pharmaceuticals Inc.
Genomic Health
Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
Medivation, Inc., a Pfizer company
Sanofi Genzyme
Tolmar Pharmaceuticals, Inc.
 
AUAER ensures that all educational activities are developed and implemented independent of the control and/or influence of any commercial interests (ACCME: SCS1)
 
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
 
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
 
CME Information
For all inquiries regarding CME credit email: education@AUAnet.org

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation

Accreditation Period

Course opens: 
06/01/2017
Course expires: 
06/01/2018
Please login or register to take this course.